Hemab Therapeutics (NASDAQ:COAG) Stock Price Up 5.8% – Still a Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s stock price shot up 5.8% on Wednesday . The stock traded as high as $33.63 and last traded at $33.32. Approximately 61,732 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 265,036 shares. The stock had previously closed at $31.49.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on COAG. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Hemab Therapeutics in a research report on Friday, June 26th. Jefferies Financial Group began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price for the company. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. Finally, Wedbush initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $42.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Hemab Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $41.40.

Hemab Therapeutics Trading Up 9.6%

The stock has a market capitalization of $1.61 billion and a PE ratio of -1.44. The business’s 50 day moving average price is $28.01.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. bought 2,675,000 shares of Hemab Therapeutics stock in a transaction that occurred on Monday, May 4th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the acquisition, the director owned 6,149,096 shares of the company’s stock, valued at $110,683,728. The trade was a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders acquired 2,970,541 shares of company stock valued at $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.